We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBRE icon
276
CBRE Group
CBRE
$42.8B
$225K ﹤0.01%
+1,673
New +$230K
BIVIW
277
BioVie Inc Warrant
BIVIW
$132K
$225K ﹤0.01%
500,000
– –
CRBG icon
278
Corebridge Financial
CRBG
$15.4B
$224K ﹤0.01%
+7,830
New +$212K
POOL icon
279
Pool Corp
POOL
$6.73B
$223K ﹤0.01%
+1,038
New +$207K
MKTX icon
280
MarketAxess Holdings
MKTX
$5.75B
$222K ﹤0.01%
+1,952
New +$278K
CHYM
281
Chime Financial
CHYM
$12.8B
$221K ﹤0.01%
+10,800
New +$210K
CPRT icon
282
Copart
CPRT
$31.2B
$217K ﹤0.01%
+7,709
New +$249K
UDR icon
283
UDR
UDR
$11.7B
$217K ﹤0.01%
+5,424
New +$201K
PWR icon
284
Quanta Services
PWR
$93.9B
$216K ﹤0.01%
+300
New +$205K
GPN icon
285
Global Payments
GPN
$24.5B
$215K ﹤0.01%
+2,960
New +$204K
JOBY icon
286
Joby Aviation
JOBY
$6.67B
$213K ﹤0.01%
+23,924
New +$231K
PPC icon
287
Pilgrim's Pride
PPC
$7.26B
$213K ﹤0.01%
+7,582
New +$233K
CPRX
288
DELISTED
Catalyst Pharmaceutical
CPRX
$212K ﹤0.01%
+6,733
New +$199K
CACC icon
289
Credit Acceptance
CACC
$6.28B
$209K ﹤0.01%
329
-732
-69% -$392K
BRBR icon
290
BellRing Brands
BRBR
$1.21B
$209K ﹤0.01%
+16,155
New +$195K
WST icon
291
West Pharmaceutical
WST
$23.9B
$208K ﹤0.01%
+578
New +$177K
PR
292
Permian Resources
PR
$19.6B
$206K ﹤0.01%
+11,214
New +$225K
VITL icon
293
Vital Farms
VITL
$426M
$206K ﹤0.01%
+17,699
New +$197K
TSN icon
294
Tyson Foods
TSN
$18.1B
$204K ﹤0.01%
+3,567
New +$223K
CRL icon
295
Charles River Laboratories
CRL
$13.8B
$204K ﹤0.01%
+900
New +$160K
IDA icon
296
Idacorp
IDA
$7.85B
$204K ﹤0.01%
+1,346
New +$194K
CNS icon
297
Cohen & Steers
CNS
$4.11B
$204K ﹤0.01%
+2,674
New +$189K
AOS icon
298
A.O. Smith
AOS
$8.22B
$203K ﹤0.01%
+3,243
New +$197K
CLF icon
299
Cleveland-Cliffs
CLF
$7.13B
$203K ﹤0.01%
21,652
-8,643
-29% -$95K
GPI icon
300
Group 1 Automotive
GPI
$3.59B
$203K ﹤0.01%
+697
New +$228K
10 11
12
13 14

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.